BIOMAT Database Logo BIOMAT Database Logo

Ageing and acetylator phenotype as determined by administration of sulphadimidine. 1985

A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000107 Acetylation Formation of an acetyl derivative. (Stedman, 25th ed) Acetylations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D013418 Sulfamethazine A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides. Benzenesulfonamide, 4-amino-N-(4,6-dimethyl-2-pyrimidinyl)-,Sulfadimidine,Sulphamethazine,Sulfadimezine,Sulphamezathine

Related Publications

A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza
Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine.
January 1986, European journal of clinical pharmacology,
A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza
Ageing and acetylator phenotype.
January 1985, European journal of clinical pharmacology,
A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza
The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine.
March 1973, Tubercle,
A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza
Possible optimization of sulphadimidine dosage for acetylator phenotyping.
August 1991, Japanese journal of pharmacology,
A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza
Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
January 1984, International journal of clinical pharmacology research,
A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza
Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
January 1984, European journal of clinical pharmacology,
A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza
Endralazine and acetylator phenotype.
May 1983, Lancet (London, England),
A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza
Isoniazid acetylator phenotype.
February 1989, Indian pediatrics,
A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza
Acetylator phenotype and lupus erythematosus.
January 1981, Clinical pharmacokinetics,
A E Pontiroli, and A De Pasqua, and L Bonisolli, and G Pozza
Dihydralazine therapy and acetylator phenotype.
March 1979, International journal of clinical pharmacology and biopharmacy,
Copied contents to your clipboard!